TOP TIERMARKET NEWSWIRE
News & sentiment

DYNE THERAPEUTICS IN (DYN) — News & AI sentiment

DYNE THERAPEUTICS IN (DYN) news roundup. 3 stories in the past week, 16 over 30 days. Average 30-day sentiment is 54.9/100. Recent insider activity (SEC Form 4, 90-day window): 1 purchases totalling $40K and 8 sales totalling $65.7M — net selling of $65.6M. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →
24h stories
0
7d stories
3
avg sentiment 50.7/100
30d stories
16
avg sentiment 54.9/100
Insider net (90d)
$65.6M
1 buys · 8 sells
Congress (90d)
0
0 buys · 0 sells

DYN news in the last 24 hours, 7 days, 30 days and 90 days

How much DYN coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time windowDYN storiesAvg AI sentimentRead
Last 24 hours0—no coverage
Last 7 days350.7/100DYN headlines →
Last 30 days1654.9/100DYN headlines →
Last 90 days4447.6/100DYN headlines →

Latest stories on DYN

5d ago
6d ago
6d ago
Sep 30
Stifel reiterates Dyne Therapeutics stock rating on trial data
Investing.com Analyst Ratings56 · neutralanalyst
Sep 30
Wainwright cuts Dyne Therapeutics stock price target on DM1 assumptions
Investing.com Analyst Ratings34 · bearishanalyst
Sep 30
Cantor Fitzgerald reiterates Dyne Therapeutics stock rating
Investing.com Analyst Ratings50 · neutralanalyst
Sep 30
Jefferies reiterates Dyne Therapeutics stock rating on trial data
Investing.com Analyst Ratings56 · neutralanalyst
Sep 30
Sep 30
Dyne Therapeutics stock rises on positive DM1 trial results
Investing.com Markets71 · bullishproduct/pr
Sep 29
Dyne Therapeutics, Inc. (DYN) files 8-K
SEC 8-K50 · neutralgeneral
Sep 29
Sep 29
Sep 29
Sep 29
Sep 29
Sep 28
Sep 17
Sep 17
Sep 14
Sep 9
Sep 9
Dyne Therapeutics stock price target lowered to $30 by RBC Capital
Investing.com Analyst Ratings34 · bearishanalyst
Sep 9
Sep 9
Sep 9
Sep 9
Open DYN in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →